{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T03:06:41Z","timestamp":1780628801380,"version":"3.54.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,27]],"date-time":"2016-02-27T00:00:00Z","timestamp":1456531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","jfma-online.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.jfma.2016.02.003","type":"journal-article","created":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:56:51Z","timestamp":1462064211000},"page":"475-480","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Serial follow-up of presurgical treatment using pasireotide long-acting release with or without octreotide long-acting release for na\u00efve active acromegaly"],"prefix":"10.1016","volume":"115","author":[{"given":"Jan-Shun","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ham-Min","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien-Chun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2016.02.003_bib1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1210\/jc.2007-1191","article-title":"Mortality in acromegaly: a metaanalysis","volume":"93","author":"Dekkers","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jfma.2016.02.003_bib2","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1530\/eje.1.02036","article-title":"Consensus statement: medical management of acromegaly","volume":"153","author":"Melmed","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jfma.2016.02.003_bib3","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11102-012-0384-x","article-title":"Changes in acromegaly treatment over four decades in Spain: analysis of the Spanish Acromegaly Registry (REA)","volume":"16","author":"Sesmilo","year":"2013","journal-title":"Pituitary"},{"key":"10.1016\/j.jfma.2016.02.003_bib4","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1530\/eje.0.1460707","article-title":"SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile","volume":"146","author":"Bruns","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jfma.2016.02.003_bib5","first-page":"140","article-title":"Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas","volume":"86","author":"Saveanu","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jfma.2016.02.003_bib6","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1210\/jc.2008-0315","article-title":"Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial","volume":"93","author":"Carlsen","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jfma.2016.02.003_bib7","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3171\/jns.2006.104.6.899","article-title":"Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates","volume":"104","author":"Losa","year":"2006","journal-title":"J Neurosurg"},{"key":"10.1016\/j.jfma.2016.02.003_bib8","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1530\/EJE-08-0498","article-title":"Results of surgical and somatostatin analog therapies and their combination in acromegaly: a retrospective analysis of the German Acromegaly Register","volume":"159","author":"Petersenn","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jfma.2016.02.003_bib9","first-page":"43","article-title":"Clinical applications of somatostatin analogs for growth hormone-secreting pituitary adenomas","volume":"8","author":"Wang","year":"2014","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jfma.2016.02.003_bib10","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1210\/jc.2013-2480","article-title":"Pasireotide versus octreotide in acromegaly: a head-to-head superiority study","volume":"99","author":"Colao","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jfma.2016.02.003_bib11","first-page":"645","article-title":"Improvement in remission rates of the first operation in acromegalic patients","volume":"22","author":"Demir","year":"2012","journal-title":"Turk Neurosurg"},{"key":"10.1016\/j.jfma.2016.02.003_bib12","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000095533","article-title":"Transsphenoidal microsurgery for newly diagnosed acromegaly: a personal view after more than 1,000 operations","volume":"83","author":"Ludecke","year":"2006","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.jfma.2016.02.003_bib13","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1210\/jcem.86.1.7154","article-title":"The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy","volume":"86","author":"Peacey","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jfma.2016.02.003_bib14","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1172\/JCI19933","article-title":"Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis","volume":"114","author":"Murray","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jfma.2016.02.003_bib15","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s11102-014-0585-6","article-title":"Erratum to: Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study","volume":"18","author":"Sheppard","year":"2015","journal-title":"Pituitary"},{"key":"10.1016\/j.jfma.2016.02.003_bib16","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/j.1365-2265.2011.03982.x","article-title":"Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure","volume":"74","author":"Carlsen","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.jfma.2016.02.003_bib17","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1177\/147323001204000213","article-title":"Preoperative lanreotide treatment improves outcome in patients with acromegaly resulting from invasive pituitary macroadenoma","volume":"40","author":"Li","year":"2012","journal-title":"J Int Med Res"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664616300018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664616300018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T15:58:29Z","timestamp":1536767909000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664616300018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0929664616300018"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2016.02.003","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serial follow-up of presurgical treatment using pasireotide long-acting release with or without octreotide long-acting release for na\u00efve active acromegaly","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2016.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016, Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}